Wockhardt Jumps After FDA Clears Zaynich NDA

Introduction

Wockhardt, a leading pharmaceutical and biotechnology innovator, witnessed a dramatic surge in its stock price during Monday’s intraday trading on December 01, with shares climbing 19.3% to touch an impressive high of ₹1,473 apiece. This strong rebound followed a period of weakness but was swiftly reversed after the company announced a major regulatory milestone for its novel antibiotic Zaynich.

US FDA Accepts New Drug Application for Zaynich

Wockhardt revealed in a regulatory filing that the United States Food and Drug Administration (US FDA) has officially accepted its New Drug Application (NDA) for Zaynich, a groundbreaking first-in-class antibiotic. Originally submitted on September 30, 2025, the acceptance of this application marks a monumental achievement not only for Wockhardt but also for the Indian pharmaceutical landscape. The company highlighted that this is the first-ever instance of an Indian pharmaceutical firm filing and securing acceptance for an NDA involving a New Chemical Entity (NCE) by the US FDA.

A Novel Antibiotic Designed to Combat MDR and XDR Pathogens

Zaynich is a powerful combination of Zidebactam, a β-lactam enhancer, and Cefepime, a fourth-generation cephalosporin. Engineered to fight multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens, it targets critical bacteria such as Pseudomonas Aeruginosa, Acinetobacter Baumannii, and carbapenem-resistant strains. Its approval pathway underscores its crucial role in addressing rising antimicrobial resistance.

Fast Track Designation and Priority Review Pathway

The US FDA has granted Zaynich a Fast Track designation, acknowledging its potential to meet urgent and unmet medical needs. Under this program, the FDA has committed to prioritizing the review of the Zaynich NDA, accelerating the timeline for potential approval and availability.

A Decade-Long Scientific Journey

Wockhardt emphasized that Zaynich represents one of the world’s most extensively studied antibiotics over the past decade. Since beginning its development program in 2011, the company has successfully navigated complex clinical, non-clinical, and regulatory challenges. This long-term commitment showcases Wockhardt’s scientific leadership and dedication to combating global antimicrobial resistance.

A Historic Moment for Indian Pharmaceutical Innovation

In its statement, Wockhardt expressed immense pride over this milestone, stating that the FDA’s acceptance of the NDA celebrates not only the company’s achievements but also the capability of Indian scientific innovation on the global platform. The breakthrough reinforces the organization’s mission to develop advanced anti-infective solutions for worldwide health challenges.

Wockhardt Share Price Performance

Wockhardt’s stock had been under pressure since reaching a one-year high in July 2025, sliding 22% amid profit-booking and market volatility. This decline followed a remarkable multibagger rally from April 2023 to July 2025, during which the share price skyrocketed from ₹154 to ₹1,714—a staggering 1,000% growth.
Despite recent weakness, the stock has still managed a modest 3% gain in 2025 so far. Over a three-year period, Wockhardt continues to display robust long-term performance with an impressive 513% return, reflecting investor confidence in its innovation-led growth strategy.

About the Author

Sorit Chaudhary

Author

View All Posts